Risovic Verica, Man Damen, Sivak Olena, Lee Stephen D, Wasan Kishor M
Division of Pharmaceutics and Biopharmaceutics, University of British Columbia, 2146 East Mall Avenue, Vancouver, BC, Canada.
Drug Dev Ind Pharm. 2006 Jun;32(5):609-15. doi: 10.1080/03639040500529010.
The purpose of this study was to assess the lipid lowering and plasma cholesteryl ester transfer protein (CETP) activity following administration of simvastatin to rabbits fed a high fat/cholesterol diet.
Male New Zealand white rabbits were housed in individual cages and fed a standard diet for 7 days. After 7 days, animals were fed 10 g of a regular chow diet plus 100 g of the same diet supplemented with 0.5% (w/v) cholesterol and 14.0% (w/v) coconut oil for 28 days. Following 28 days on this diet, the animals were randomized based on plasma cholesterol and triglyceride levels, into a group of control animals and a group (n = 6) of animals fed 100 g of cholesterol/coconut diet plus 10 g regular chow diet containing simvastatin (3 mg/kg/day) for an additional 28 days. Blood samples were taken from the marginal ear vein prior to and 28 days after the initiation of drug treatment. Plasma was harvested and stored at 4 degrees C prior to lipid analysis. Plasma total cholesterol and triglyceride levels were quantified using enzymatic kits. HDL (high-density lipoproteins) cholesterol levels were determined using the dextran sulfate-Mg(2+) precipitation method. ApoB cholesterol levels were determined by subtracting total cholesterol from HDL cholesterol. Cholesteryl ester transfer protein (CETP) activity was determined by standard assay methods.
We observed that simvastatin significantly reduced total plasma cholesterol, triglyceride, and apoB cholesterol compared to non-treated controls. Simvastatin treatment did not alter serum CETP activity compared to non-treated controls.
These findings suggest that decreasing plasma lipid levels by treatment with simvastatin is not due to changes in serum CETP activity in rabbits fed a high fat/cholesterol diet.
本研究旨在评估给予高脂/高胆固醇饮食的兔子服用辛伐他汀后的降脂效果及血浆胆固醇酯转运蛋白(CETP)活性。
雄性新西兰白兔单笼饲养,给予标准饮食7天。7天后,给动物喂食10克常规饲料加100克添加了0.5%(w/v)胆固醇和14.0%(w/v)椰子油的相同饲料,持续28天。在此饮食28天后,根据血浆胆固醇和甘油三酯水平将动物随机分为一组对照动物和一组(n = 6)喂食100克胆固醇/椰子饮食加10克含辛伐他汀(3毫克/千克/天)的常规饲料的动物,再持续28天。在药物治疗开始前和开始后28天从边缘耳静脉采集血样。采集血浆并在4℃下储存,用于脂质分析。使用酶试剂盒定量血浆总胆固醇和甘油三酯水平。采用硫酸葡聚糖 - 镁(2+)沉淀法测定高密度脂蛋白(HDL)胆固醇水平。通过从HDL胆固醇中减去总胆固醇来测定载脂蛋白B胆固醇水平。采用标准测定方法测定胆固醇酯转运蛋白(CETP)活性。
我们观察到,与未治疗的对照组相比,辛伐他汀显著降低了血浆总胆固醇、甘油三酯和载脂蛋白B胆固醇。与未治疗的对照组相比,辛伐他汀治疗未改变血清CETP活性。
这些发现表明,在给予高脂/高胆固醇饮食的兔子中,用辛伐他汀治疗降低血浆脂质水平并非由于血清CETP活性的改变。